Abstract
Introduction

The major hereditary causes of hypophosphatemic osteomalacia associated with fibroblast growth factor 23 (FGF23) are X-linked hypophosphatemic rickets/osteomalacia (XLH), autosomal dominant hypophosphatemic rickets/osteomalacia (ADHR) and autosomal recessive hypophosphatemic rickets/ osteomalacia (ARHR). In acquired cases, tumor-induced osteomalacia (TIO) is the most representative disorder. Since these disorders have similar clinical manifestations, differentiation between these conditions is often difficult in adultonset cases. However, diagnosis of TIO is therapeutically beneficial because clinical manifestations are expected to improve after the removal of the responsible tumor (1).
Here F i g u r e 1 . T h e p a t i e n t ' s u p p e r t r u n k p r e s e n t e d wi t h ma r k e d p e c t u s c a r i n a t u m. He was healthy until 5 years before admission and had no family history of metabolic bone disease. On physical examination, the height was 160 cm and the weight was 60 kg. He had pectus carinatum without a limb deformity (Fig. 1) . Plain radiograph revealed marked thoracic kyphosis (Fig. 2) and pseudofracture in the right femoral neck (Fig. 3) T a b l e 1 . Re s u l t s o f L a b o r a t o r y T e s t s o n Ad mi s s i (9) and then are inherited in an X-linked dominant manner (10) . In XLH, muscle weakness seen in other causes of osteomalacia is typically absent (11) and enthesopathy, which is bone proliferation at the sites of ligament, tendon and joint capsule, is a common finding, particularly in adults (11) (18) . In contrast, dipyridamole therapy has reportedly had no effect on serum phosphate or its urinary excretion in children with XLH (19) . In the present (18, 20) 
